BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16278412)

  • 1. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
    Karacay H; Brard PY; Sharkey RM; Chang CH; Rossi EA; McBride WJ; Ragland DR; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Nov; 11(21):7879-85. PubMed ID: 16278412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
    Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
    Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
    Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
    Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
    Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
    Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
    Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
    Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
    Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
    Rossi EA; Chang CH; Losman MJ; Sharkey RM; Karacay H; McBride W; Cardillo TM; Hansen HJ; Qu Z; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7122s-7129s. PubMed ID: 16203811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice.
    Schoffelen R; van der Graaf WT; Franssen G; Sharkey RM; Goldenberg DM; McBride WJ; Rossi EA; Eek A; Oyen WJ; Boerman OC
    J Nucl Med; 2010 Nov; 51(11):1780-7. PubMed ID: 21051650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.